These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8239901)

  • 1. [Maternal serum markers and prenatal screening for trisomy 21].
    Leymarie P; Leporrier N
    Arch Fr Pediatr; 1993 May; 50(5):455-7. PubMed ID: 8239901
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple marker screening.
    Dickerson VM
    West J Med; 1994 Aug; 161(2):161. PubMed ID: 7524245
    [No Abstract]   [Full Text] [Related]  

  • 3. Ethical concerns and future directions in maternal screening for Down syndrome.
    Elkins TE; Brown D
    Womens Health Issues; 1995; 5(1):15-20. PubMed ID: 7742644
    [No Abstract]   [Full Text] [Related]  

  • 4. [Screening by maternal serum markers for Down's syndrome].
    Liu JT; Hao N; Sun NH; Wang FY; Xu YH; Gai MY; Bian XM; Yang JQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):156-9. PubMed ID: 12905710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prenatal diagnosis of Down's syndrome based on the biochemical screening of maternal serum markers].
    Arbuzova SB; Nikolenko MI; Khlevnaia LA; Fedotova OO; Solov'eva VD; Malova SA
    Tsitol Genet; 1998; 32(1):66-71. PubMed ID: 9695254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fetal trisomy 21 risk evaluation by measurement of maternal serum markers].
    Dhondt JL
    Ann Biol Clin (Paris); 1998; 56(4):471-5. PubMed ID: 9754284
    [No Abstract]   [Full Text] [Related]  

  • 7. [The value and drawbacks of evaluation of the risk of fetal trisomy 21].
    Taieb J; Benattar C; Audibert F; Frydman R; Lindenbaum A
    Contracept Fertil Sex; 1997 Apr; 25(4):269-76. PubMed ID: 9229515
    [No Abstract]   [Full Text] [Related]  

  • 8. Triploidy identified through second-trimester serum screening.
    Huang T; Alberman E; Wald N; Summers AM
    Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in antenatal screening for Down syndrome.
    Wald NJ; Hackshaw AK
    Baillieres Best Pract Res Clin Obstet Gynaecol; 2000 Aug; 14(4):563-80. PubMed ID: 10985931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Unusual behavior of serum markers in risk evaluation for trisomy 21].
    Guibaud S; Boisson C; Chambon V; Simplot A
    Ann Biol Clin (Paris); 1998; 56(4):439-44. PubMed ID: 9754279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum screening of pregnant women reveals Down syndrome. Analysis of biochemical markers for earlier detection].
    Christiansen M; Larsen SO; Nørgaard-Pedersen B
    Lakartidningen; 1997 Dec; 94(51-52):4898-902. PubMed ID: 9454010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prenatal screening for Down's syndrome].
    Qin Q; Christiansen M; Norgaard-Pedersen B
    Zhonghua Fu Chan Ke Za Zhi; 1997 Nov; 32(11):694-7. PubMed ID: 9639772
    [No Abstract]   [Full Text] [Related]  

  • 15. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 46,XY,i(21q) identified by maternal serum screening.
    Meyers CM; Ghori S; Roberson AE; Blitzer MG; Cohen MM
    Md Med J; 1997 Feb; 46(2):88-9. PubMed ID: 9029908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of low serum alpha fetoprotein].
    Hod M; Friedman S; Pick I; Ovadia J
    Harefuah; 1989 Nov; 117(10):305-10. PubMed ID: 2482239
    [No Abstract]   [Full Text] [Related]  

  • 19. Trisomy 18 fetuses with cystic hygroma linked to positive maternal serum Down's syndrome Triple test screening result.
    Celentano C; Guanciali-Franchi PE; Liberati M; Prefumo F; Palka G; Rotmensch S
    J Med Screen; 2005; 12(4):203. PubMed ID: 16417699
    [No Abstract]   [Full Text] [Related]  

  • 20. Prenatal screening for Down syndrome.
    Ogle RF; Chitty LS
    Hosp Med; 1998 Aug; 59(8):632-6. PubMed ID: 9829057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.